Enterprise Value

19.25M

Cash

10.01M

Avg Qtr Burn

-8.436M

Short % of Float

8.37%

Insider Ownership

4.14%

Institutional Own.

7.70%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vyleesi® (bremelanotide) MC4r Agonist Details
Sexual dysfunction, Sexual desire disorder, Influenza

Approved

Quarterly sales

PL9643 Details
Eye disease , Dry eye syndrome

Phase 3

Update

Bremelanotide + GLP-1 Details
Obesity, Metabolic disorder

Phase 2

Data readout

PL8177 Details
Chronic inflammatory disorder, Inflammatory disease, Bowel disorder, Ulcerative colitis

Phase 2

Data readout

Bremelanotide + PDE5i Details
Erectile dysfunction

Phase 2

Data readout

Bremelanotide Details
Diabetic Kidney Disease

Phase 2

Data readout

Failed

Discontinued

PL8177 Details
Eye disease , Inflammatory disease

Failed

Discontinued

Failed

Discontinued